​

Privia Health Group (PRVA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PRVA Stock Forecast

Privia Health Group stock forecast is as follows: an average price target of $23.00 (represents a 14.26% upside from PRVA’s last price of $20.13) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.

PRVA Price Target

The average price target for Privia Health Group (PRVA) is $23.00 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $22.00. This represents a potential 14.26% upside from PRVA's last price of $20.13.

PRVA Analyst Ratings

Buy

According to 12 Wall Street analysts, Privia Health Group's rating consensus is 'Buy'. The analyst rating breakdown for PRVA stock is 0 'Strong Buy' (0.00%), 10 'Buy' (83.33%), 2 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Privia Health Group Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 26, 2024Michael HaRobert W. Baird$24.00$21.0314.12%19.23%
Aug 08, 2024Elizabeth AndersonEvercore ISI$22.00$19.3513.70%9.29%
May 20, 2024Andrew MokBarclays$19.00$16.9012.43%-5.61%
May 15, 2024Jailendra SinghTruist Financial$24.00$18.0532.96%19.23%
Dec 08, 2022UBS$30.00$23.3128.70%49.03%
Nov 17, 2022Canaccord CanaccordCanaccord Genuity$43.00$24.0478.87%113.61%
Nov 11, 2022Leerink Partners$39.00$28.5336.70%93.74%
Aug 25, 2022Canaccord Genuity$50.00$42.4917.67%148.39%
Aug 12, 2022Truist Financial$48.00$38.4324.90%138.45%
Aug 12, 2022Credit Suisse$41.00$38.556.36%103.68%
Aug 12, 2022Cowen & Co.$44.00$38.4314.49%118.58%
Aug 12, 2022Sandy DraperGuggenheim$51.00$37.8734.67%153.35%
Aug 12, 2022Leerink Partners$46.00$37.8721.47%128.51%
Jul 25, 2022David MacDonaldTruist Financial$40.00$36.419.86%98.71%
May 13, 2022Canaccord Genuity$29.00$24.0520.58%44.06%
Apr 28, 2022BTIG$35.00$23.9546.14%73.87%

The latest Privia Health Group stock forecast, released on Aug 26, 2024 by Michael Ha from Robert W. Baird, set a price target of $24.00, which represents a 14.12% increase from the stock price at the time of the forecast ($21.03), and a 19.23% increase from PRVA last price ($20.13).

Privia Health Group Price Target by Period

1M3M12M
# Anlaysts--4
Avg Price Target--$22.25
Last Closing Price$20.13$20.13$20.13
Upside/Downside-100.00%-100.00%10.53%

In the current month, the average price target of Privia Health Group stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Privia Health Group's last price of $20.13. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 10, 2024KeyBancOverweightInitialise
Aug 14, 2024RBC CapitalEqual-WeightEqual-WeightHold
Aug 14, 2024Evercore ISIUnderperformUnderperformHold
Aug 08, 2024Evercore ISIOutperformOutperformHold
May 20, 2024BarclaysEqual-WeightEqual-WeightHold
Feb 03, 2023Goldman SachsBuyInitialise
Dec 08, 2022UBSBuyInitialise
Nov 11, 2022Canaccord GenuityBuyBuyHold
Aug 25, 2022Canaccord GenuityBuyBuyHold
Aug 12, 2022GuggenheimBuyBuyHold
Aug 12, 2022Credit SuisseOutperformOutperformHold
Aug 12, 2022Cowen & Co.OutperformOutperformHold
Aug 12, 2022SVB LeerinkOutperformOutperformHold
May 13, 2022Canaccord GenuityBuyBuyHold
May 13, 2022SVB LeerinkOutperformOutperformHold
Apr 28, 2022BTIGBuyInitialise
Feb 22, 2022Cowen & Co.OutperformUpgrade
Jan 04, 2022JefferiesBuyInitialise

Privia Health Group's last stock rating was published by KeyBanc on Oct 10, 2024. The company Initialise its PRVA rating from "null" to "Overweight".

Privia Health Group Financial Forecast

Privia Health Group Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
Revenue------------$440.83M$417.28M$413.35M$386.28M$364.42M$342.90M$335.54M$313.80M$275.33M$251.52M$225.76M$213.61M
Avg Forecast$523.21M$533.19M$520.80M$515.44M$473.33M$479.58M$470.01M$455.68M$419.31M$414.23M$411.50M$393.55M$427.11M$428.21M$409.17M$396.61M$332.64M$318.22M$313.33M$295.12M$226.09M$215.15M$214.98M$197.32M
High Forecast$553.39M$563.94M$550.83M$545.17M$500.63M$507.24M$497.12M$483.89M$430.25M$414.75M$411.50M$393.55M$429.60M$436.87M$432.76M$419.48M$351.83M$318.22M$313.33M$295.12M$226.09M$215.15M$214.98M$197.32M
Low Forecast$488.62M$497.94M$486.36M$481.36M$442.03M$447.86M$438.93M$407.31M$398.64M$413.71M$411.50M$393.55M$418.50M$419.56M$382.11M$370.38M$310.65M$318.22M$313.33M$295.12M$226.09M$215.15M$214.98M$197.32M
# Analysts5454434813734756322223456
Surprise %------------1.03%0.97%1.01%0.97%1.10%1.08%1.07%1.06%1.22%1.17%1.05%1.08%

Privia Health Group's average Quarter revenue forecast for Mar 24 based on 4 analysts is $393.55M, with a low forecast of $393.55M, and a high forecast of $393.55M. PRVA's average Quarter revenue forecast represents a -10.72% decrease compared to the company's last Quarter revenue of $440.83M (Dec 23).

Privia Health Group EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts5454434813734756322223456
EBITDA------------$3.19M$6.97M$9.58M$8.05M$3.38M$-3.42M$-4.08M$-10.43M$-18.32M$-10.57M$-191.80M$8.35M
Avg Forecast$-16.87M$-17.20M$-16.80M$-16.62M$-15.27M$-15.47M$-15.16M$-14.70M$-13.52M$-13.36M$-13.27M$-12.69M$-13.77M$-13.81M$-13.20M$-12.79M$-10.73M$-10.26M$-10.11M$-17.73M$-7.29M$-6.94M$-260.69M$-6.36M
High Forecast$-15.76M$-16.06M$-15.69M$-15.52M$-14.26M$-14.44M$-14.16M$-13.14M$-12.86M$-13.34M$-13.27M$-12.69M$-13.50M$-13.53M$-12.32M$-11.95M$-10.02M$-10.26M$-10.11M$-14.19M$-7.29M$-6.94M$-208.55M$-6.36M
Low Forecast$-17.85M$-18.19M$-17.77M$-17.58M$-16.15M$-16.36M$-16.03M$-15.61M$-13.88M$-13.38M$-13.27M$-12.69M$-13.86M$-14.09M$-13.96M$-13.53M$-11.35M$-10.26M$-10.11M$-21.28M$-7.29M$-6.94M$-312.82M$-6.36M
Surprise %-------------0.23%-0.50%-0.73%-0.63%-0.32%0.33%0.40%0.59%2.51%1.52%0.74%-1.31%

4 analysts predict PRVA's average Quarter EBITDA for Mar 24 to be $-12.69M, with a high of $-12.69M and a low of $-12.69M. This is -497.64% lower than Privia Health Group's previous annual EBITDA (Dec 23) of $3.19M.

Privia Health Group Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts5454434813734756322223456
Net Income------------$2.84M$5.64M$7.27M$7.32M$17.78M$556.00K$-11.38M$-18.09M$-11.89M$-10.89M$-173.49M$5.40M
Avg Forecast$9.38M$13.00M$11.09M$8.05M$8.87M$9.94M$7.96M$6.42M$6.31M$6.00M$5.68M$6.00M$5.24M$6.19M$7.04M$7.73M$1.52M$2.61M$253.27K$-31.52M$-15.83M$-16.92M$-234.51M$5.43M
High Forecast$10.08M$13.98M$11.92M$8.65M$9.53M$10.69M$8.55M$10.09M$9.46M$6.17M$5.73M$6.02M$7.33M$6.65M$7.56M$8.31M$1.63M$2.61M$253.27K$-25.21M$-15.83M$-16.92M$-187.60M$5.43M
Low Forecast$8.57M$11.88M$10.13M$7.36M$8.11M$9.09M$7.27M$3.67M$3.15M$5.83M$5.63M$5.98M$3.14M$5.66M$6.43M$7.06M$1.39M$2.61M$253.27K$-37.82M$-15.83M$-16.92M$-281.41M$5.43M
Surprise %------------0.54%0.91%1.03%0.95%11.70%0.21%-44.94%0.57%0.75%0.64%0.74%0.99%

Privia Health Group's average Quarter net income forecast for Mar 24 is $6.00M, with a range of $5.98M to $6.02M. PRVA's average Quarter net income forecast represents a 111.35% increase compared to the company's last Quarter net income of $2.84M (Dec 23).

Privia Health Group SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts5454434813734756322223456
SG&A------------$35.85M$34.47M$32.76M$31.24M$33.33M$37.31M$37.93M$40.77M$43.12M$38.50M$179.84M$17.18M
Avg Forecast$64.05M$65.27M$63.75M$63.10M$57.94M$58.71M$57.53M$55.78M$51.33M$50.71M$50.37M$48.18M$52.28M$52.42M$50.09M$48.55M$40.72M$38.95M$38.36M$73.39M$27.68M$26.34M$26.32M$24.15M
High Forecast$67.74M$69.03M$67.43M$66.74M$61.28M$62.09M$60.85M$59.23M$52.67M$50.77M$50.37M$48.18M$52.59M$53.48M$52.98M$51.35M$43.07M$38.95M$38.36M$88.07M$27.68M$26.34M$26.32M$24.15M
Low Forecast$59.81M$60.95M$59.54M$58.92M$54.11M$54.82M$53.73M$49.86M$48.80M$50.64M$50.37M$48.18M$51.23M$51.36M$46.77M$45.34M$38.03M$38.95M$38.36M$58.71M$27.68M$26.34M$26.32M$24.15M
Surprise %------------0.69%0.66%0.65%0.64%0.82%0.96%0.99%0.56%1.56%1.46%6.83%0.71%

Privia Health Group's average Quarter SG&A projection for Mar 24 is $48.18M, based on 4 Wall Street analysts, with a range of $48.18M to $48.18M. The forecast indicates a 34.39% rise compared to PRVA last annual SG&A of $35.85M (Dec 23).

Privia Health Group EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts5454434813734756322223456
EPS------------$0.02$0.05$0.06$0.06$0.16$0.01$-0.10$-0.17$-0.11$-0.10$-1.69$0.05
Avg Forecast$0.07$0.10$0.09$0.06$0.07$0.08$0.06$0.05$0.05$0.05$0.05$0.05$0.04$0.05$0.06$0.06$0.01$0.02-$-0.01$-0.13$-0.14$-0.85$0.04
High Forecast$0.08$0.11$0.09$0.07$0.08$0.08$0.07$0.08$0.08$0.05$0.05$0.05$0.06$0.05$0.06$0.07$0.01$0.02-$-0.01$-0.13$-0.14$-0.85$0.04
Low Forecast$0.07$0.09$0.08$0.06$0.06$0.07$0.06$0.03$0.03$0.05$0.04$0.05$0.02$0.04$0.05$0.06$0.01$0.02-$-0.01$-0.13$-0.14$-0.85$0.04
Surprise %------------0.55%0.98%1.12%0.98%13.24%0.24%-49.48%14.35%0.87%0.74%1.98%1.20%

According to 4 Wall Street analysts, Privia Health Group's projected average Quarter EPS for Mar 24 is $0.05, with a low estimate of $0.05 and a high estimate of $0.05. This represents a 110.13% increase compared to PRVA previous annual EPS of $0.02 (Dec 23).

Privia Health Group Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
EVHEvolent Health$10.87$33.00203.59%Buy
SLPSimulations Plus$30.04$47.0056.46%Buy
DHDefinitive Healthcare$4.46$6.0836.32%Hold
CERTCertara$11.40$15.0031.58%Buy
HQYHealthEquity$91.09$108.3318.93%Buy
PRVAPrivia Health Group$20.79$23.0010.63%Buy
HSTMHealthStream$31.97$29.00-9.29%Buy

PRVA Forecast FAQ

Is Privia Health Group a good buy?

Yes, according to 12 Wall Street analysts, Privia Health Group (PRVA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 83.33% of PRVA's total ratings.

What is PRVA's price target?

Privia Health Group (PRVA) average price target is $23 with a range of $22 to $24, implying a 14.26% from its last price of $20.13. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Privia Health Group stock go up soon?

According to Wall Street analysts' prediction for PRVA stock, the company can go up by 14.26% (from the last price of $20.13 to the average price target of $23), up by 19.23% based on the highest stock price target, and up by 9.29% based on the lowest stock price target.

Can Privia Health Group stock reach $30?

PRVA's average twelve months analyst stock price target of $23 does not support the claim that Privia Health Group can reach $30 in the near future.

What are Privia Health Group's analysts' financial forecasts?

Privia Health Group's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.88B (high $1.99B, low $1.74B), average EBITDA is $-60.588M (high $-55.993M, low $-64.144M), average net income is $33.19M (high $38.86M, low $28.13M), average SG&A $229.96M (high $243.46M, low $212.52M), and average EPS is $0.264 (high $0.309, low $0.224). PRVA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.09B (high $2.21B, low $1.95B), average EBITDA is $-67.491M (high $-63.028M, low $-71.384M), average net income is $41.52M (high $44.63M, low $37.95M), average SG&A $256.17M (high $270.94M, low $239.23M), and average EPS is $0.33 (high $0.355, low $0.302).

Did the PRVA's actual financial results beat the analysts' financial forecasts?

Based on Privia Health Group's last annual report (Dec 2023), the company's revenue was $1.66B, which missed the average analysts forecast of $1.66B by -0.20%. Apple's EBITDA was $27.18M, missing the average prediction of $-53.573M by -150.74%. The company's net income was $23.08M, missing the average estimation of $26.19M by -11.88%. Apple's SG&A was $134.32M, missing the average forecast of $203.34M by -33.94%. Lastly, the company's EPS was $0.19, missing the average prediction of $0.208 by -8.77%. In terms of the last quarterly report (Dec 2023), Privia Health Group's revenue was $440.83M, beating the average analysts' forecast of $427.11M by 3.21%. The company's EBITDA was $3.19M, missing the average prediction of $-13.775M by -123.17%. Privia Health Group's net income was $2.84M, missing the average estimation of $5.24M by -45.79%. The company's SG&A was $35.85M, missing the average forecast of $52.28M by -31.43%. Lastly, the company's EPS was $0.0227, missing the average prediction of $0.0416 by -45.48%